ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect

Core Viewpoint - Investors are expected to focus on the sales performance of ChromaDex Corp.'s marketed product, Niagen, and updates on the pipeline during the third-quarter 2024 results report on October 31, with revenue estimates at $23.70 million and earnings at 1 cent per share [1][4]. Group 1: Product Performance - ChromaDex markets Niagen as a superior-quality NAD+ booster available in several countries, including the United States, and it is the sole active ingredient in its dietary supplement, Tru Niagen [3]. - Revenues in the last reported quarter increased year over year, driven by higher sales of Tru Niagen and steady e-commerce performance, a trend expected to continue in the upcoming quarter [4]. Group 2: Pipeline Developments - The FDA granted Orphan Drug Designation and Rare Pediatric Disease Designation to ChromaDex's investigational candidate, nicotinamide riboside chloride (NRC), for treating ataxia telangiectasia, a rare neurodegenerative disease [5]. - Updates on the planned investigational new drug application for NRC are anticipated during the third-quarter earnings call, with human clinical studies to begin pending FDA clearance [6]. Group 3: Financial Performance and Expectations - ChromaDex shares have increased by 156.6% year-to-date, contrasting with a 3.9% decrease in the industry [7]. - The company has a strong earnings surprise history, beating estimates in each of the last four quarters with an average surprise of 83.34% [7]. - ChromaDex has an Earnings ESP of 0.00%, with both the Most Accurate Estimate and the Zacks Consensus Estimate at 1 cent per share, and currently holds a Zacks Rank of 2 [9].